Migraine Pipeline and Impact Updates: What Health Execs Should KnowA new report highlights physical, social, and economic challenges of migraine.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
Generic Viagra Could Save Patients MillionsBoth Pfizer and Teva have brought out generic versions of Viagra, a boon to the millions of men with erectile dysfunction.
Teva Laying Off Employees in Israel and United StatesThe world's largest generic drug manufacturer is laying off thousands of employees.
5 facts to know about the new asthma drugFDA recently approved reslizumab (Cinqair, Teva Pharmaceuticals), an injectable used with other asthma medicines for the maintenance treatment of severe asthma. Here are the top 5 facts to know about Cinqair.
Balancing opioid benefits, dangersOpioids are powerful clinical tools that effectively treat pain and have a place in therapy, but it can be difficult to manage the dangers. Here's a look at some of the abuse-deterrent drugs on the horizon.
The 4 most problematic drug shortagesDrug shortages are significant public health threats. They can delay, or even deny, critical care for patients. Here are the four drugs in shortage that are among the most problematic.
New forum expands access to biosimilarsThe non-profit Biosimilars Forum was launched in May 2015 to offer credible, sustained, and unbiased education about biosimilars. The founding members of the Biosimilars Forum represent the majority of companies with the most significant US biosimilars development portfolios.
Teva’s Mylan bid set to shake up industryTeva Pharmaceutical’s unsolicited $40 billion offer to acquire Mylan N.V. is expected to shake up the pharmaceutical industry, especially in the areas of generic and specialty drugs. A Teva acquisition of Mylan would be the biggest health care deal of the year so far and the largest acquisition ever proposed by an Israeli company, according to S.&P. Capital IQ, The New York Times reported.
FDA approves Copaxone for MS; problems persistThe FDA today approved the first generic version of Copaxone (glatiramer acetate injection) for treating patients with relapsing forms of multiple sclerosis (MS) on April 16.